|Bid||5.14 x 100|
|Ask||14.95 x 100|
|Day's range||7.64 - 7.88|
|52-week range||4.31 - 18.64|
|PE ratio (TTM)||N/A|
|Earnings date||19 Feb 2018 - 23 Feb 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||10.38|
“We are pleased to finalize this agreement which has a compelling strategic logic for both companies,” said Arthur Higgins, President and CEO of Depomed. As previously announced, on December 4, 2017, Depomed signed a definitive Commercialization Agreement with Collegium under the terms of which, Collegium will commercialize NUCYNTA and in exchange Depomed will receive a royalty rate on all NUCYNTA revenues based on certain net sales thresholds.
Collegium rocketed to a 22-month high Tuesday after striking a deal with Depomed to commercialize its painkiller Nucynta.
The boost to U.S. stocks from tax-reform proved short-lived, with the Dow Jones Industrial Average finishing up less than 60 points, while the Nasdaq Composite and S&P 500 closed down 1.1% and 0.1%, respectively. The negative momentum has spilled over into Asia-Pacific markets with benchmark indices in Australia, Japan and Korea all in the red on Tuesday morning. In U.S. after-hours stock news: Collegium Pharmaceutical (COLL) jumped 9% after announcing that it has entered into a definitive agreement with Depomed to commercialize Nucynta tablets in the U.S. Depomed (DEPO) jumped 4.9% on the same agreement. Ascena Retail Group (ASNA) slumped 20% after the fashion retailer posted a 50% year--on-year drop in FY18 first quarter earnings and offered weak guidance for the upcoming quarter.
DepoMed Inc. announced Monday afternoon that it will allow Collegium Pharmaceutical Inc. to handle sales of its most lucrative product, the Nucynta line of painkillers, and slash its workforce. DepoMed ...
Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Depomed, Inc. . The complaint is brought on behalf of all purchasers of Depomed securities between February 26, 2015 and August 7, 2017, for alleged violations of the Securities Exchange Act of 1934 by Depomed's officers and directors.
Glancy Prongay & Murray LLP reminds investors of the October 17, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Depomed, Inc.
Law Offices of Howard G. Smith reminds investors of the October 17, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Depomed, Inc.
Scott+Scott, Attorneys at Law, LLP , a national shareholder and consumer rights litigation firm, reminds investors that October 17, 2017, is the deadline to move for lead plaintiff status in the securities class action pending against Depomed, Inc.